Nexviadyme (Avalglucosidase Alfa)

Avalglucosidase alfa, the active ingredient in Nexviadyme, is an enzyme replacement therapy presented as an intravenous solution for infusion use. It is indicated for the treatment of Pompe disease, a glycogen storage disorder, in patients of all ages.

GNH USA supplies Nexviadyme as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, specialty clinics and pharmacies worldwide, ensuring quality, regulatory compliance and reliable cold‑chain logistics for biologic products.

Nexviadyme is used to address the lysosomal glycogen accumulation that characterises Pompe disease and related acid α‑glucosidase deficiencies.

Infantile‑onset Pompe disease: improves survival, motor milestones and reduces cardiac hypertrophy. Late‑onset Pompe disease: stabilizes respiratory function, maintains muscle strength and slows disease progression. Acid α‑glucosidase deficiency (any age): reduces lysosomal glycogen storage and supports overall metabolic balance.

Nexviadyme may be associated with a range of adverse reactions observed during clinical use.

Common Side Effects: - Infusion‑related reactions such as chills, fever or flushing. - Headache. - Nausea or vomiting. - Fatigue.

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions. - Cardiac arrhythmias. - Pulmonary hypertension. - Development of neutralising antibodies that reduce efficacy. - Severe infusion reactions requiring medical intervention.

Prior to initiating Nexviadyme, clinicians should consider several precautionary measures to optimise safety.

Immune response: assess for anti‑drug antibodies before and during therapy. Infusion rate: start at the recommended rate and adjust based on patient tolerance. Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. Concomitant medications: review for potential interactions that may affect infusion safety. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nexviadyme can interact with other medicines; awareness of potential interactions helps manage risk.

Major Interactions (Avoid): - Live vaccines: avoid concurrent administration due to possible immune modulation. - Potent immunosuppressants: may reduce therapeutic efficacy. - Certain anticholinergic agents: may increase risk of infusion‑related reactions.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of infusion reactions. - Corticosteroids: often used to manage hypersensitivity but require monitoring. - Other enzyme therapies: monitor for additive effects on immune response.